• 3-Bromopyruvate Induces Ferroptosis to Overcome Cetuximab Re

  2026-05-09

  This study demonstrates that co-treatment with 3-bromopyruvate and cetuximab overcomes intrinsic and acquired cetuximab resistance in colorectal cancer by inducing autophagy-dependent ferroptosis. The mechanistic findings clarify how FOXO3a signaling restoration sensitizes resistant cancer cells, providing a potential therapeutic avenue for refractory colorectal cancer.

• JC-1 Mitochondrial Membrane Potential Assay Kit: Precision i

  2026-05-08

  Explore the advanced use of the JC-1 Mitochondrial Membrane Potential Assay Kit for immunometabolic research and apoptosis detection. This article unveils assay design insights, reference-driven innovations, and practical strategies that distinguish it from existing content.

• Dabigatran in Thrombin Inhibition Assays: Advanced Workflows

  2026-05-08

  Dabigatran (Pradaxa) is a gold-standard direct thrombin inhibitor, enabling precise study of human coagulation in vitro. Discover advanced experimental workflows, troubleshooting strategies, and cutting-edge applications that set APExBIO’s Dabigatran apart for translational anticoagulation research.

• Optimizing IR-1061 Liposomes for High-Resolution NIR-II Imag

  2026-05-07

  This study introduces a rationally designed NIR-II fluorescent nanosystem using IR-1061 encapsulated in liposomes, analyzing how phospholipid charge and dye concentration affect fluorescence for in vivo vascular imaging. The approach achieves long-circulating, high-contrast angiography, highlighting organic fluorophores' potential over inorganic alternatives for deep tissue imaging.

• CK2 and ERK8 Inhibitor: Precision Control in Kinase Signalin

  2026-05-07

  Explore how the CK2 and ERK8 inhibitor, a potent small molecule inhibitor, enables precise interrogation of kinase signaling and phase separation mechanisms. This article offers a unique, evidence-based perspective on optimizing biochemical assays with 2-(4,5,6,7-tetrabromo-2-(dimethylamino)-1H-benzo[d]imidazol-1-yl)acetic acid.

• LINC01278-Induced Autophagy Suppresses Uveal Melanoma via mT

  2026-05-06

  This study demonstrates that the long noncoding RNA LINC01278 acts as a tumor suppressor in uveal melanoma by inducing autophagy through inhibition of the mTOR signaling pathway. The findings offer mechanistic insights into autophagy regulation in cancer and suggest new therapeutic avenues targeting the LINC01278-mTOR axis.

• EdU Flow Cytometry Assay Kits (Cy3): Precision Cell Cycle An

  2026-05-06

  Unlock high-sensitivity, multiplexed DNA synthesis detection with EdU Flow Cytometry Assay Kits (Cy3). Streamline your cell proliferation and genotoxicity studies using click chemistry for robust, reproducible results—without harsh denaturation. Discover advanced troubleshooting and workflow optimization strategies tailored for cutting-edge biomedical research.

• Macrophage EP4 Loss Accelerates Atherosclerosis via CD36 Pat

  2026-05-05

  This study reveals that deficiency of the EP4 receptor in macrophages intensifies atherosclerosis through enhanced CD36-mediated lipid uptake and a shift toward pro-inflammatory M1 polarization. The findings clarify a mechanistic link between EP4 signaling, foam cell formation, and plaque progression, offering new targets for cardiovascular disease intervention.

• Aurora Kinase A Drives Trained Immunity via SAM Metabolism C

  2026-05-05

  Li et al. provide compelling evidence that Aurora kinase A (AurA) is essential for sustaining trained immunity by regulating endogenous S-adenosylmethionine (SAM) metabolism. Their work reveals a mechanistic link between AurA activity, epigenetic chromatin remodeling, and immune memory in innate cells, informing future strategies in immunology and cancer research.

• LINC01278 Regulates Autophagy via mTOR Suppression in Uveal

  2026-05-04

  A recent study identifies LINC01278 as a tumor-suppressive lncRNA that induces autophagy and inhibits uveal melanoma progression by suppressing the mTOR signaling pathway. These mechanistic insights provide new candidates for prognostic biomarkers and therapeutic strategies targeting autophagy regulation in cancer.

• Moesin as a Biomarker of Endothelial Injury in Sepsis: Evide

  2026-05-04

  The referenced study establishes moesin (MSN) as a promising biomarker for endothelial injury in sepsis, correlating serum MSN levels with disease severity and mechanistic endothelial disruption. The integration of in vivo, patient, and cellular models provides mechanistic clarity and translational relevance to sepsis research.

• Practical Guidance for Using Y-27632 (ROCK Inhibitor) in Cel

  2026-05-03

  Y-27632 is a selective ROCK inhibitor used to modulate cytoskeletal dynamics, making it valuable for researchers studying stress fiber disruption, ROCK signaling, and related cellular processes. It is not intended for diagnostic or medical applications and should be used following specific workflow and storage recommendations for consistent results.

• Torin2: Redefining mTOR Inhibition Strategy in Translational

  2026-05-02

  This article delivers a fresh, evidence-driven perspective on Torin2’s unique mechanistic advantages as a next-generation mTOR inhibitor, offering actionable guidance for translational researchers. Building on recent findings in in vitro drug response evaluation, we bridge molecular pharmacology with workflow strategy, highlight distinct protocol parameters, and position Torin2 as a catalyst for next-level cancer research. The discussion escalates beyond conventional product literature by integrating mechanistic insights, translational context, and lessons from recent doctoral work on drug response metrics.

• Clodronate Liposomes for In Vivo Macrophage Depletion Workfl

  2026-05-01

  Clodronate Liposomes enable precise, reproducible in vivo macrophage depletion, allowing researchers to dissect immune microenvironment functions and resistance mechanisms in complex disease models. Leveraging robust apoptosis induction and multi-route administration, this reagent is the gold standard for tissue-specific immune cell modulation.

• Brain-to-Spinal Circuits Modulate Mechanical Allodynia Later

  2026-05-01

  Huo et al. (2023) identify a brain-to-spinal circuit involving Oprm1-expressing neurons in the lateral parabrachial nucleus and Pdyn neurons in the hypothalamus that regulates the laterality and duration of mechanical allodynia in mice. Their work clarifies inhibitory pathways, particularly the hypothalamic dynorphin-spinal κ-opioid receptor system, that restrict the spread and persistence of pain hypersensitivity after injury—offering mechanistic insights highly relevant to pain modulation research.

388 records 8/26 page Previous Next First page 上5页 678910 下5页 Last page